← SynDRA
MITOGLITAZONE
SynDRA canonical compound SYN0004955 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | INS |
|---|
| Mechanism of action | Insulin sensitizer |
|---|
All known targets
Mechanisms of action (all sources)
- Insulin sensitizer
- MPC1L INHIBITOR
- INSR MODULATOR
Cross-references
Synonyms
- CAY-10415
- J730.386F
- MSD-9
- MSDC-0160
- PNU-91325
- U-91325
- Mitoglitazone (TN)
- MSDC 0160
- CAY 10415
- RefChem:159088
- DTXCID101747539
- CAY10415
- MFCD00916084
- UNII-29I7RP18RG
- Pioglitazone impurity 27
- Pioglitazone Impurity 54
- SCHEMBL622605
- US9562012, mitoglitazone
- Mitoglitazone (MSDC-0160)
- MSDC0160
- orb1305270
- SCHEMBL18538169
- CHEBI:94409
- GTPL11303
- IRNJSRAGRIZIHD-UHFFFAOYSA-N
- Mitoglitazone, >=98% (HPLC)
- BDBM228129
- GLXC-07208
- HMS6018A19
- EX-A1483
- s7453
- AKOS026750561
- CS-6405
- SB17325
- MSDC-0160(CAY10415)
- AC-32632
- AS-73799
- CAY10415(MSDC-0160)?
- DA-51623
Look up MITOGLITAZONE in the interactive SynDRA portal →